New Alzheimer's Drug's Coverage Highlights The Negative Bias Dominating The Coverage Of Our New Antiobesity Medications
On Thursday the FDA approved Leqembi, a new drug for people with Alzheimer’s, which has been shown to maybe, in some cases, slow (not stop, not reverses) cognitive decline for 5-18 months, and in other cases, either do nothing, or rarely, cause serious and life threatening brain swelling and bleeding that have at times led to death.